Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Biohit Oyj Class B is the publicly traded Series B share of Biohit Oyj, a Finnish biotechnology company founded in 1988 and headquartered in Helsinki. It specializes in the development, manufacture, and marketing of diagnostic tests, analysis systems, and related products for research institutions, healthcare providers, and industrial applications. The company's portfolio includes diagnostic tests for various medical conditions, advanced systems for diagnostic analysis, monoclonal antibodies, and innovative products that bind carcinogenic acetaldehyde into harmless compounds to mitigate health risks associated with this substance. Additionally, Biohit operates service laboratories and offers instruments supporting precision diagnostics, particularly in gastroenterology through tools like the Gastropanel test. Classified in the healthcare sector under medical devices and specialties, Biohit Oyj Class B shares represent a small-cap growth stock with around 15 million shares outstanding, playing a niche role in advancing health technology solutions globally.
€2.64
€0.06 (-2.22%)
Live · 06:42 PM
Margins and capital returns are both well above average: 20.39% operating margin, ROIC at 20.66%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 10.1% YoY with margins expanding 2.5pp. However, free cash flow softened 841%, worth monitoring whether this is timing or structural.
Free cash flow declined 841% versus the prior year, cash generation momentum has weakened. Negative free cash flow of -€1M. The business is consuming cash, not generating it.
14.7x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€16M
▲ +10.1% YoY
Net Income (TTM)
€3M
▲ +6.6% YoY
Op. Margin
20.39%
▲ +2.5pp YoY
ROIC
20.66%
▲ +0.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€1M
▼ -840.8% YoY
Op. Cash Flow (TTM)
-€748K
▼ -227.6% YoY
Net Debt
-€3M
Net Cash Position
Cash & Equiv.
€5M
3Y CAGR: +12.8%
Continue Research
At a P/E of 14.7, Biohit Oyj Class B (BIOBV.XHEL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Biohit Oyj Class B scores 65/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Biohit Oyj Class B scores 65 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 20.4% operating margin and a 20.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh BIOBV.XHEL's valuation and scores 65/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.